Literature DB >> 30477009

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.

Dickran Kazandjian1, Neha Korde2, Sham Mailankody2, Elizabeth Hill1, William D Figg3, Mark Roschewski1, Ola Landgren2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30477009      PMCID： PMC6440717          DOI： 10.1001/jamaoncol.2018.5457

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  6 in total

1.  Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.

Authors:  Neha Korde; Mark Roschewski; Adriana Zingone; Mary Kwok; Elisabet E Manasanch; Manisha Bhutani; Nishant Tageja; Dickran Kazandjian; Sham Mailankody; Peter Wu; Candis Morrison; Rene Costello; Yong Zhang; Debra Burton; Marcia Mulquin; Diamond Zuchlinski; Liz Lamping; Ashley Carpenter; Yvonne Wall; George Carter; Schuyler C Cunningham; Verena Gounden; Tristan M Sissung; Cody Peer; Irina Maric; Katherine R Calvo; Raul Braylan; Constance Yuan; Maryalice Stetler-Stevenson; Diane C Arthur; Katherine A Kong; Li Weng; Malek Faham; Liza Lindenberg; Karen Kurdziel; Peter Choyke; Seth M Steinberg; William Figg; Ola Landgren
Journal:  JAMA Oncol       Date:  2015-09       Impact factor: 31.777

Review 2.  A look backward and forward in the regulatory and treatment history of multiple myeloma: Approval of novel-novel agents, new drug development, and longer patient survival.

Authors:  Dickran Kazandjian; Ola Landgren
Journal:  Semin Oncol       Date:  2016-11-16       Impact factor: 4.929

3.  Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

Authors:  Brian G M Durie; Antje Hoering; Muneer H Abidi; S Vincent Rajkumar; Joshua Epstein; Stephen P Kahanic; Mohan Thakuri; Frederic Reu; Christopher M Reynolds; Rachael Sexton; Robert Z Orlowski; Bart Barlogie; Angela Dispenzieri
Journal:  Lancet       Date:  2016-12-23       Impact factor: 79.321

4.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Authors:  A Keith Stewart; S Vincent Rajkumar; Meletios A Dimopoulos; Tamás Masszi; Ivan Špička; Albert Oriol; Roman Hájek; Laura Rosiñol; David S Siegel; Georgi G Mihaylov; Vesselina Goranova-Marinova; Péter Rajnics; Aleksandr Suvorov; Ruben Niesvizky; Andrzej J Jakubowiak; Jesus F San-Miguel; Heinz Ludwig; Michael Wang; Vladimír Maisnar; Jiri Minarik; William I Bensinger; Maria-Victoria Mateos; Dina Ben-Yehuda; Vishal Kukreti; Naseem Zojwalla; Margaret E Tonda; Xinqun Yang; Biao Xing; Philippe Moreau; Antonio Palumbo
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

5.  Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.

Authors:  David S Siegel; Meletios A Dimopoulos; Heinz Ludwig; Thierry Facon; Hartmut Goldschmidt; Andrzej Jakubowiak; Jesus San-Miguel; Mihaela Obreja; Julie Blaedel; A Keith Stewart
Journal:  J Clin Oncol       Date:  2018-01-17       Impact factor: 44.544

6.  Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.

Authors:  O Landgren; S Devlin; M Boulad; S Mailankody
Journal:  Bone Marrow Transplant       Date:  2016-09-05       Impact factor: 5.483
  6 in total
  10 in total

Review 1.  Second malignancies in multiple myeloma; emerging patterns and future directions.

Authors:  Kylee Maclachlan; Benjamin Diamond; Francesco Maura; Jens Hillengass; Ingemar Turesson; C Ola Landgren; Dickran Kazandjian
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-11       Impact factor: 3.020

2.  Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma.

Authors:  Bachisio Ziccheddu; Giulia Biancon; Filippo Bagnoli; Chiara De Philippis; Francesco Maura; Even H Rustad; Matteo Dugo; Andrea Devecchi; Loris De Cecco; Marialuisa Sensi; Carolina Terragna; Marina Martello; Tina Bagratuni; Efstathios Kastritis; Meletios A Dimopoulos; Michele Cavo; Cristiana Carniti; Vittorio Montefusco; Paolo Corradini; Niccolo Bolli
Journal:  Blood Adv       Date:  2020-03-10

3.  Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.

Authors:  Benjamin A Derman; Ankit Kansagra; Jeffrey Zonder; Andrew T Stefka; David L Grinblatt; Larry D Anderson; Sandeep Gurbuxani; Sunil Narula; Shayan Rayani; Ajay Major; Andrew Kin; Ken Jiang; Theodore Karrison; Jagoda Jasielec; Andrzej J Jakubowiak
Journal:  JAMA Oncol       Date:  2022-09-01       Impact factor: 33.006

Review 4.  The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?

Authors:  Dickran Kazandjian; Clifton C Mo; Ola Landgren; Paul G Richardson
Journal:  Br J Haematol       Date:  2020-06-05       Impact factor: 8.615

5.  Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma.

Authors:  Even H Rustad; Malin Hultcrantz; Venkata D Yellapantula; Theresia Akhlaghi; Caleb Ho; Maria E Arcila; Mikhail Roshal; Akshar Patel; Denise Chen; Sean M Devlin; Austin Jacobsen; Ying Huang; Jeffrey E Miller; Elli Papaemmanuil; Ola Landgren
Journal:  PLoS One       Date:  2019-03-22       Impact factor: 3.240

6.  Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.

Authors:  Phoebe A Huang; Shaunna L Beedie; Cindy H Chau; David J Venzon; Sheryl Gere; Dickran Kazandjian; Neha Korde; Sham Mailankody; Ola Landgren; William D Figg
Journal:  Sci Rep       Date:  2019-10-16       Impact factor: 4.379

Review 7.  Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma.

Authors:  Ola Landgren; Pieter Sonneveld; Andrzej Jakubowiak; Mohamad Mohty; Karim S Iskander; Khalid Mezzi; David S Siegel
Journal:  Leukemia       Date:  2019-07-24       Impact factor: 11.528

8.  Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

Authors:  Shaji K Kumar; Susanna J Jacobus; Adam D Cohen; Matthias Weiss; Natalie Callander; Avina K Singh; Terri L Parker; Alexander Menter; Xuezhong Yang; Benjamin Parsons; Pankaj Kumar; Prashant Kapoor; Aaron Rosenberg; Jeffrey A Zonder; Edward Faber; Sagar Lonial; Kenneth C Anderson; Paul G Richardson; Robert Z Orlowski; Lynne I Wagner; S Vincent Rajkumar
Journal:  Lancet Oncol       Date:  2020-08-28       Impact factor: 41.316

9.  Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma.

Authors:  Venkata Yellapantula; Malin Hultcrantz; Even H Rustad; Ester Wasserman; Dory Londono; Robert Cimera; Amanda Ciardiello; Heather Landau; Theresia Akhlaghi; Sham Mailankody; Minal Patel; Juan Santiago Medina-Martinez; Juan Esteban Arango Ossa; Max Fine Levine; Niccolo Bolli; Francesco Maura; Ahmet Dogan; Elli Papaemmanuil; Yanming Zhang; Ola Landgren
Journal:  Blood Cancer J       Date:  2019-12-11       Impact factor: 11.037

Review 10.  Minimal Residual Disease in Multiple Myeloma: State of the Art and Applications in Clinical Practice.

Authors:  Alessandro Gozzetti; Donatella Raspadori; Francesca Bacchiarri; Anna Sicuranza; Paola Pacelli; Ilaria Ferrigno; Dania Tocci; Monica Bocchia
Journal:  J Pers Med       Date:  2020-09-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.